Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel M Altmann

Showing results (121-130 of 147) with videos related to

Pageof 15
Sort By:
Journal for Immunotherapy of Cancer|October 1, 2021
Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapyDavid J Pinato, Sam M Murray, Alejandro Forner, et al.
Cell Reports Methods|August 17, 2022
Quantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody responseIvan Doykov, Tomas Baldwin, Justyna Spiewak, et al.
The Lancet. Microbe|July 12, 2021
Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy studyRishi K Gupta, Joshua Rosenheim, Lucy C Bell, et al.
The Lancet. Gastroenterology & Hepatology|December 8, 2022
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort studyZhigang Liu, Kaixing Le, Xin Zhou, et al.
Communications Medicine|April 29, 2026
Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVIDMark A Faghy, Rob C I Wüst, Daniel M Altmann, et al.
Gut|July 28, 2022
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemicNicholas A Kennedy, Malik Janjua, Neil Chanchlani, et al.
Gut|April 12, 2019
Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trialEdward S Chambers, Claire S Byrne, Douglas J Morrison, et al.
Science (New York, N.Y.)|May 1, 2021
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine doseCatherine J Reynolds, Corinna Pade, Joseph M Gibbons, et al.
Ebiomedicine|October 1, 2022
Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infectionGabriella Captur, James C Moon, Constantin-Cristian Topriceanu, et al.
The Lancet. Rheumatology|January 24, 2024
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trialAbhishek Abhishek, Nicholas Peckham, Corinna Pade, et al.
Pageof 15

Showing results (121-130 of 147) with videos related to

Sort By:
Pageof 15
Journal for Immunotherapy of Cancer|October 1, 2021
Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapyDavid J Pinato, Sam M Murray, Alejandro Forner, et al.
Cell Reports Methods|August 17, 2022
Quantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody responseIvan Doykov, Tomas Baldwin, Justyna Spiewak, et al.
The Lancet. Microbe|July 12, 2021
Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy studyRishi K Gupta, Joshua Rosenheim, Lucy C Bell, et al.
The Lancet. Gastroenterology & Hepatology|December 8, 2022
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort studyZhigang Liu, Kaixing Le, Xin Zhou, et al.
Communications Medicine|April 29, 2026
Current status and future perspectives on the mechanistic and pathophysiological understanding of long COVIDMark A Faghy, Rob C I Wüst, Daniel M Altmann, et al.
Gut|July 28, 2022
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemicNicholas A Kennedy, Malik Janjua, Neil Chanchlani, et al.
Gut|April 12, 2019
Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trialEdward S Chambers, Claire S Byrne, Douglas J Morrison, et al.
Science (New York, N.Y.)|May 1, 2021
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine doseCatherine J Reynolds, Corinna Pade, Joseph M Gibbons, et al.
Ebiomedicine|October 1, 2022
Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infectionGabriella Captur, James C Moon, Constantin-Cristian Topriceanu, et al.
The Lancet. Rheumatology|January 24, 2024
Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trialAbhishek Abhishek, Nicholas Peckham, Corinna Pade, et al.
Pageof 15